Reads well :-)
A couple of quick highlights:
With annualised expenses reduced by about $4 million, together with increased sales means we continue to anticipate that the second half of this year will be cash flow positive. Achieving that will be a significant milestone for the company and augers well for future growth to be achieved.
We are planning a sales drive into the important North American market where our applications are extremely relevant and where we believe we have large sales potential. This work has been built on earlier surveys and is being carried out in conjunction with AUSTRADE.
- Forums
- ASX - By Stock
- ASV
- announcement out .. letter to shareholders
announcement out .. letter to shareholders
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ASV (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.40M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200000 | 2.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.4¢ | 55500 | 1 |
Last trade - 09.59am 25/11/2024 (20 minute delay) ? |
Featured News
ASV (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online